These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 36987498)

  • 1. The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes.
    Gelhorn HL; Osumili B; Brown K; Ross MM; Schulz A; Fernandez G; Boye KS
    Patient Prefer Adherence; 2023; 17():793-805. PubMed ID: 36987498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States.
    Mody RR; Meyer KL; Ward JM; O'Day KB
    Diabetes Ther; 2023 Dec; 14(12):2045-2055. PubMed ID: 37770706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
    Boye KS; Sapin H; Dong W; Williamson S; Lee CJ; Thieu VT
    Diabetes Ther; 2023 Nov; 14(11):1867-1887. PubMed ID: 37668888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
    Boye KS; Thieu VT; Sapin H; Lee CJ; Landó LF; Brown K; Bray R; Wiese RJ; Patel H; Rodríguez Á; Yu M
    Diabetes Ther; 2023 Nov; 14(11):1833-1852. PubMed ID: 37526908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.
    Gelhorn HL; Poon JL; Davies EW; Paczkowski R; Curtis SE; Boye KS
    Patient Prefer Adherence; 2015; 9():1611-22. PubMed ID: 26635470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.
    Mather KJ; Mari A; Heise T; DeVries JH; Hua M; Urva S; Coskun T; Haupt A; Heine RJ; Pratt E; Thomas MK; Milicevic Z
    J Clin Endocrinol Metab; 2024 May; ():. PubMed ID: 38795393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
    Rodriguez PJ; Goodwin Cartwright BM; Gratzl S; Brar R; Baker C; Gluckman TJ; Stucky NL
    JAMA Intern Med; 2024 Jul; ():. PubMed ID: 38976257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.
    Bi Y; Lu S; Tang J; Du L; Ji L
    Diabetes Ther; 2024 May; 15(5):1125-1137. PubMed ID: 38494574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes.
    Vázquez LA; Romera I; Rubio-de Santos M; Escalada J
    Diabetes Ther; 2023 Nov; 14(11):1771-1784. PubMed ID: 37713104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan.
    Gelhorn HL; Bacci ED; Poon JL; Boye KS; Suzuki S; Babineaux SM
    Patient Prefer Adherence; 2016; 10():1337-48. PubMed ID: 27524889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials.
    Rosenstock J; Vázquez L; Del Prato S; Franco DR; Weerakkody G; Dai B; Landó LF; Bergman BK; Rodríguez A
    Diabetes Care; 2023 Nov; 46(11):1986-1992. PubMed ID: 37673061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.
    Skelley JW; Swearengin K; York AL; Glover LH
    J Am Pharm Assoc (2003); 2024; 64(1):204-211.e4. PubMed ID: 37940101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. People With Diabetes and Caregivers Prefer Rescue Glucagon Treatment With a Wider Storage Temperature Range and a Nasal Administration, When Efficacy is Similar: A Discrete Choice Experiment in Spain.
    Mitchell BD; Rentz AM; Kummer S; Yan Y; Heidenreich S; Krucien N; Artime E; Osumili B; Rubio M; Gelhorn HL
    J Diabetes Sci Technol; 2023 Nov; 17(6):1623-1633. PubMed ID: 35533142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US Population Eligibility and Estimated Impact of Tirzepatide Treatment on Obesity Prevalence and Cardiovascular Disease Events.
    Wong ND; Karthikeyan H; Fan W
    Cardiovasc Drugs Ther; 2024 Jun; ():. PubMed ID: 38850368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors.
    Sims TJ; Boye KS; Robinson S; Kennedy-Martin T
    Patient Prefer Adherence; 2022; 16():1919-1939. PubMed ID: 35958887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond.
    Sood A; Kaur P; Syed O; Sood A; Aronow WS; Borokhovsky B; Bhatia V; Gupta R
    Expert Rev Clin Pharmacol; 2024 Mar; 17(3):235-246. PubMed ID: 38265050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferences of Patients with Amyotrophic Lateral Sclerosis for Intrathecal Drug Delivery: Choosing between an Implanted Drug-Delivery Device and Therapeutic Lumbar Puncture.
    Seo J; Saurkar S; Fernandez GS; Das A; Goutman SA; Heidenreich S
    Patient; 2024 Mar; 17(2):161-177. PubMed ID: 38097873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weighing in on glucagon-like peptide-1 receptor agonists in dermatology.
    Heymann WR
    J Am Acad Dermatol; 2024 Jul; 91(1):29-30. PubMed ID: 38692437
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply: Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
    Bradley CL; McMillin SM; Hwang AY; Sherrill CH
    Ann Pharmacother; 2024 Apr; 58(4):446-447. PubMed ID: 38247049
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.